Deleted Tweets From Scott Gottlieb, R-D.C.

#FDA unveiled today a comprehensive new framework for how we intend to advance the use of real world evidence and real world data in support of drug development https://t.co/7qa70KmTtq

RT @FDASpox: FDA releases new its new strategic framework to advance the use of real-world evidence in support of the developmen… https://t.co/P4Zh32GjHh

RT @ESchattner: A beautiful picture, the @FDAOncology breast cancer team on stage during a session with advocates at #sabcs18 & TY!… https://t.co/rR1aTif1Hr

RT @RAPSorg: .@US_FDA Will Allow Observational Studies to Support Effectiveness Determinations, New Framework Says | #Regulatory… https://t.co/JaynvT4V4K

RT @LungAssociation: MeiLan K. Han, MD, MS, professor of internal medicine at @UMich & one of our volunteer spokespeople has been select… https://t.co/pxuoGJE0O0

There’s still time to get your flu vaccine and National Influenza Vaccination Week #NIVW! (Dec. 2-8) is the perfect time. Protect yourself and the people you care about. https://t.co/J3SEAxnUKf https://t.co/leJ0mie5RK

RT @EricTopol: I've never written anything with the words "condemned," "reckless," and "unethical" in it, but think they're all wa… https://t.co/X50wQyJn5q

RT @FDA_Drug_Info: New FDA Draft Guidance – Developing and Labeling In vitro Companion Diagnostic Devices for a Specific Group or Clas… https://t.co/dPtgsYJf1j

RT @SGottliebFDA: Robust federal partnership will be key to thwarting any efforts to ‘game’ or abuse the system with the intention to thwar… QT @FTC: FTC submits comment on @US_FDA guidance aimed at deterring abuse of citizen petition process: https://t.co/be0DaVF068)

RT @FDAfood: The FDA is alerting consumers: possible #hepatitisA contamination of Bauer’s Candies Modjeskas. Do NOT eat & throw… https://t.co/JBDb0cF2iQ

ALERT: Consumers should be aware of a recall of certain brands of infant ibuprofen oral suspension produced by Tris Pharma that have a higher than normal potency and have the potential for adverse effects. More information can be found at: https://t.co/GdBxQMFh12

THREAD: #FDAVoices It’s our responsibility to make sure that encouraging trends in drug development, driven in large part by new diagnostics, flourish in the coming years - we need to modernize the regulatory framework for in vitro clinical tests. https://t.co/cBfg95Sutf

Today we released our new strategic Framework for gathering data from real-world evidence settings. #FDA uses this information in our drug and biologic development efforts to ultimately improve patient health. https://t.co/KdhsXJ2TlT https://t.co/m5b3H9suXS

Use of RWD has the potential to make our medical product development processes more efficient and help lower the cost of development. Our goal is to close the evidence gap between the information we use to make decisions and the evidence collected by the medical community.

#FDAVoices FDA supports a new, more modern approach that would focus our review resources where they would make the most difference for advancing safety, innovation, and improvements in patient care and where the risk is highest. https://t.co/cBfg95Sutf

#FDAVoices Currently, new tests that undergo rigorous FDA review must demonstrate they are analytically and clinically valid, but laboratory developed tests (LDTs) are not being required to demonstrate to FDA that they meet these same standards. https://t.co/cBfg95Sutf

#FDAVoices Patients rely on diagnostic test information to make decisions about their health regardless of who develops the test. We shouldn’t subject similar tests to different scientific standards just because they are made by different developers. https://t.co/cBfg95Sutf

RT @SeanKhozin: .@US_FDA releases #realworldevidence framework, a landmark in modernizing #clinicaltrials. Includes efforts led by… https://t.co/njrMQ2OB4F

Today #FDA released our new strategic Framework for gathering data from real-world evidence settings. #FDA uses this information in our drug and biologic development efforts to ultimately improve patient health. https://t.co/EuSC5vShqy https://t.co/lTt9qgQXXm

RT @FDAOncology: SISAQOL Consortium sets 3 priorities for standardizing analysis of QoL data in RCTs: develop taxonomy of research o… https://t.co/J1gK1ZxZly

#FDA unveiled today a comprehensive new framework for how we intend to advance the use of real world evidence and real world data in support of drug development https://t.co/7qa70KmTtq

RT @FDASpox: FDA releases new its new strategic framework to advance the use of real-world evidence in support of the developmen… https://t.co/P4Zh32GjHh

RT @ESchattner: A beautiful picture, the @FDAOncology breast cancer team on stage during a session with advocates at #sabcs18 & TY!… https://t.co/rR1aTif1Hr

RT @RAPSorg: .@US_FDA Will Allow Observational Studies to Support Effectiveness Determinations, New Framework Says | #Regulatory… https://t.co/JaynvT4V4K

RT @LungAssociation: MeiLan K. Han, MD, MS, professor of internal medicine at @UMich & one of our volunteer spokespeople has been select… https://t.co/pxuoGJE0O0

There’s still time to get your flu vaccine and National Influenza Vaccination Week #NIVW! (Dec. 2-8) is the perfect time. Protect yourself and the people you care about. https://t.co/J3SEAxnUKf https://t.co/leJ0mie5RK

RT @EricTopol: I've never written anything with the words "condemned," "reckless," and "unethical" in it, but think they're all wa… https://t.co/X50wQyJn5q

RT @FDA_Drug_Info: New FDA Draft Guidance – Developing and Labeling In vitro Companion Diagnostic Devices for a Specific Group or Clas… https://t.co/dPtgsYJf1j

RT @SGottliebFDA: Robust federal partnership will be key to thwarting any efforts to ‘game’ or abuse the system with the intention to thwar… QT @FTC: FTC submits comment on @US_FDA guidance aimed at deterring abuse of citizen petition process: https://t.co/be0DaVF068)

RT @FDAfood: The FDA is alerting consumers: possible #hepatitisA contamination of Bauer’s Candies Modjeskas. Do NOT eat & throw… https://t.co/JBDb0cF2iQ

ALERT: Consumers should be aware of a recall of certain brands of infant ibuprofen oral suspension produced by Tris Pharma that have a higher than normal potency and have the potential for adverse effects. More information can be found at: https://t.co/GdBxQMFh12

THREAD: #FDAVoices It’s our responsibility to make sure that encouraging trends in drug development, driven in large part by new diagnostics, flourish in the coming years - we need to modernize the regulatory framework for in vitro clinical tests. https://t.co/cBfg95Sutf

Today we released our new strategic Framework for gathering data from real-world evidence settings. #FDA uses this information in our drug and biologic development efforts to ultimately improve patient health. https://t.co/KdhsXJ2TlT https://t.co/m5b3H9suXS

Use of RWD has the potential to make our medical product development processes more efficient and help lower the cost of development. Our goal is to close the evidence gap between the information we use to make decisions and the evidence collected by the medical community.

#FDAVoices FDA supports a new, more modern approach that would focus our review resources where they would make the most difference for advancing safety, innovation, and improvements in patient care and where the risk is highest. https://t.co/cBfg95Sutf

#FDAVoices Currently, new tests that undergo rigorous FDA review must demonstrate they are analytically and clinically valid, but laboratory developed tests (LDTs) are not being required to demonstrate to FDA that they meet these same standards. https://t.co/cBfg95Sutf

#FDAVoices Patients rely on diagnostic test information to make decisions about their health regardless of who develops the test. We shouldn’t subject similar tests to different scientific standards just because they are made by different developers. https://t.co/cBfg95Sutf

RT @SeanKhozin: .@US_FDA releases #realworldevidence framework, a landmark in modernizing #clinicaltrials. Includes efforts led by… https://t.co/njrMQ2OB4F

Today #FDA released our new strategic Framework for gathering data from real-world evidence settings. #FDA uses this information in our drug and biologic development efforts to ultimately improve patient health. https://t.co/EuSC5vShqy https://t.co/lTt9qgQXXm

RT @FDAOncology: SISAQOL Consortium sets 3 priorities for standardizing analysis of QoL data in RCTs: develop taxonomy of research o… https://t.co/J1gK1ZxZly